Title for MeetingAbstracts
Alphabetical listing of titles
Protease inhibitor drug use and adverse cardiovascular events in ambulatory HIV-infected patients.
Protease Inhibitor Experienced Patients with Protease Mutations 82A and 90M: Saquinavir Phenotype (PT) and Response to Saquinavir/Ritonavir (SQV/RTV).
Protease Inhibitor Exposure Time and Risk of Cardiovascular Disease in HIV-infected Patients.
Protease Inhibitor Resistance in HIV: Correlation between Phenotype and Genotype.
Protease inhibitor resistant HIV-1 has marked decreased fitness in vivo.
Protease inhibitor resistant HIV-1 variants containing an altered protease cleavage site.
Protease inhibitor therapy in 19 children with HIV 1 infection.
Protease inhibitor therapy in HIV-infected children pretreated with multiple antiviral drugs.
Protease inhibitor therapy in women: experience from clinical practice.
Protease inhibitor therapy is associated with longer time to relapse in patients with CMV retinitis.
Protease Inhibitor Use and Adverse Cardiovascular Outcomes in Ambulatory HIV Patients.
Protease inhibitor-associated hyperglycemia: results of switching from indinavir to nelfinavir.
Protease Inhibitor-containing HAART is Associated with Decreased In Vivo T-cell Activation Independent of its Effects on Viral Replication.
Protease inhibitor-induced lipodystrophy.
Protease inhibitor-related knowledge, attitudes and patterns of use by gender.
Protease inhibitor-resistant HIV-1 strains isolated from periods of continued CD4+ T-cell accumulation are pathogenic in human lymphoid histocultures.
Protease inhibitor-sparing regimens containing nevirapine, Efavirenz, or Abacavir achieve long-term HIV-1 Aviremia and CD4 stabilization but do not improve metabolic complications.
Protease inhibitors (PI) are associated with low rates of genotypic resistance in HIV+ homeless and marginally housed (H/M) adults.
Protease inhibitors (PI) are associated with viral load suppression in HIV+ homeless and marginally housed (H/M) adults.
Protease inhibitors (PI) in the HIV+ homeless and marginally housed (H/M): good adherence but rarely prescribed.
Protease inhibitors among injecting drug users in Amsterdam: cumulative incidence, determinants and impact.
Protease inhibitors and coronary heart disease in HIV-infected patients.
Protease inhibitors and declining AIDS deaths in New York City (NYC).
Protease inhibitors and direct viral load measurement: impact on cost of care and funding sources.
Protease inhibitors and liver transaminase enzyme in patients co-infected with HIV and hepatitis C virus (HCV).
Protease inhibitors and male impotence.
Protease inhibitors and medical service utilization in patients with HIV.
Protease inhibitors and medical service utilization in patients with HIV.
Protease inhibitors and recreational drugs: a group approach to harm minimisation and medication adherence.
Protease inhibitors are associated with declining AIDS deaths in New York City (NYC).